Cargando…
Erythropoietin-derived peptide treatment reduced neurological deficit and neuropathological changes in a mouse model of tauopathy
BACKGROUND: Prominent activation of microglial immune/inflammatory processes is a characteristic feature of brains of patients with tauopathies including Alzheimer’s disease (AD), suggesting that neuroinflammation may be a critical factor in their pathogenesis. Strategies aimed at developing new the...
Autores principales: | Choi, Yun-Beom, Dunn-Meynell, Ambrose A., Marchese, Michelle, Blumberg, Benjamin M., Gaindh, Deeya, Dowling, Peter C., Lu, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839226/ https://www.ncbi.nlm.nih.gov/pubmed/33504364 http://dx.doi.org/10.1186/s13195-020-00766-4 |
Ejemplares similares
-
In vivo Bioluminescence Imaging Used to Monitor Disease Activity and Therapeutic Response in a Mouse Model of Tauopathy
por: Dunn-Meynell, Ambrose A., et al.
Publicado: (2019) -
Prolonged Beneficial Effect of Brief Erythropoietin Peptide JM4 Therapy on Chronic Relapsing EAE
por: Gaindh, Deeya, et al.
Publicado: (2020) -
Neuropathological changes and cognitive deficits in rats transgenic for human mutant tau recapitulate human tauopathy
por: Malcolm, Janice C., et al.
Publicado: (2019) -
VPS35 regulates tau phosphorylation and neuropathology in tauopathy
por: Vagnozzi, Alana N., et al.
Publicado: (2021) -
The Effects of a Blood–Brain Barrier Penetrating Erythropoietin in a Mouse Model of Tauopathy
por: Yang, Joshua, et al.
Publicado: (2023)